Stephanie R. Wilson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stephanie R. Wilson has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- David P. Burrowes
University of Calgary, Calgary, Canada
8 shared publications Alexandra Medellin
From the Department of Diagnostic Imaging, University of Calgary, Foothills Medical Centre, 1403 29th St NW, Calgary, AB, Canada T2N 2T9
6 shared publications- David T. Fetzer
Department of Radiology, University of Texas Southwestern Medical Center, Dallas, USA
6 shared publications Christina Merrill
University of Calgary, Calgary, Canada
5 shared publications- Fabio Piscaglia
Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy
4 shared publications Kelly W. Burak
Department of Gastroenterology, University of Calgary, Calgary, Canada
4 shared publications
Latest Publications
- 21 August 2026
- Published by Springer Nature in Abdominal Radiology
- p. 1-9
HCC within LR-M on CEUS LI-RADS: preliminary analysis of washout timing & intensity
- 21 August 2026
- Published by Springer Nature in Abdominal Radiology
- p. 1-9
HCC within LR-M on CEUS LI-RADS: preliminary analysis of washout timing & intensity
- 1 September 2025
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 45 (9) , e240149
Ancillary US of the Bowel: Endovaginal US, Contrast-enhanced US, and Elastography
Color Doppler and standard gray-scale US have limitations for bowel imaging, and radiologists can improve routine bowel sonography by adding three readily available ancillary techniques: endovaginal US, contrast-enhanced US, and shear-wave elastography.
- 1 September 2025
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 45 (9) , e240149
Ancillary US of the Bowel: Endovaginal US, Contrast-enhanced US, and Elastography
Color Doppler and standard gray-scale US have limitations for bowel imaging, and radiologists can improve routine bowel sonography by adding three readily available ancillary techniques: endovaginal US, contrast-enhanced US, and shear-wave elastography.
- 4 June 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (12) , 5761-5773
The post-surgical liver: is application of treatment response assessment within the CEUS LI-RADS framework possible?
Background and purpose To appraise the inclusion of CEUS resection site evaluation in LI-RADS CEUS Nonradiation Treatment Response Assessment (TRA) v2024, currently applied for ablative therapy. We highlight the specific benefits afforded by CEUS in this effort. Methods Retrospective chart review was performed for 102 patients following surgical resection of HCC and ICC with post-operative CEUS at our center. Demographic data, surgical history, CT/MR findings, and resection site appearances on greyscale and CEUS were documented. The resection site where the tumor was originally positioned was designated as the treatment site and the resection margin as the perilesional tissue to establish equal assessment to TRA for ablative therapy. The morphology of the resection site was assigned one of three appearances, using novel descriptors: EDGE, VOID, or SURFACE DIVOT. Resection sites were evaluated for benign appearances, post-surgical changes, and tumor recurrence, and then categorized with a CEUS LI-RADS TRA score. Results 102 patients had 120 resection sites following 115 operations for 94 HCC and 8 ICC. On CEUS, 59 (49%) were characterized as EDGE, 46 (38%) as VOID, and 15 (13%) as SURFACE DIVOT, n = 120. 23 (19%) of resection sites were LR-TR VIABLE for recurrence, 91 (76%) LR-TR NONVIABLE, and 6 (5%) EQUIVOCAL, n = 120. Benign post-surgical changes developed in 23 (19%) resection sites, n = 120. 63/115 surgeries (55%) had post-operative recurrence, 40 De Novo, 17 Perilesional, and 6 Intralesional. Conclusion Our conclusions are in two categories: the first assessing the success of CEUS in the assessment of post-surgical treatment sites following liver resections. CEUS can successfully distinguish between unique post-operative appearances such as benign tissue migration, resection VOIDs resembling an intrinsic mass, and true recurrence. CEUS is thus strongly recommended for secondary surveillance following HCC and ICC resection. The second conclusion evaluates the inclusion of resection sites into the CEUS LI-RADS TRA algorithm for ablative therapies. In this regard, we believe that our study was highly successful, improving the perspective of all our staff as to what is important in the assessment of the post-surgical liver on CEUS and the method whereby this information is communicated to our referring clinicians. Graphical Abstract
- 4 June 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (12) , 5761-5773
The post-surgical liver: is application of treatment response assessment within the CEUS LI-RADS framework possible?
Background and purpose To appraise the inclusion of CEUS resection site evaluation in LI-RADS CEUS Nonradiation Treatment Response Assessment (TRA) v2024, currently applied for ablative therapy. We highlight the specific benefits afforded by CEUS in this effort. Methods Retrospective chart review was performed for 102 patients following surgical resection of HCC and ICC with post-operative CEUS at our center. Demographic data, surgical history, CT/MR findings, and resection site appearances on greyscale and CEUS were documented. The resection site where the tumor was originally positioned was designated as the treatment site and the resection margin as the perilesional tissue to establish equal assessment to TRA for ablative therapy. The morphology of the resection site was assigned one of three appearances, using novel descriptors: EDGE, VOID, or SURFACE DIVOT. Resection sites were evaluated for benign appearances, post-surgical changes, and tumor recurrence, and then categorized with a CEUS LI-RADS TRA score. Results 102 patients had 120 resection sites following 115 operations for 94 HCC and 8 ICC. On CEUS, 59 (49%) were characterized as EDGE, 46 (38%) as VOID, and 15 (13%) as SURFACE DIVOT, n = 120. 23 (19%) of resection sites were LR-TR VIABLE for recurrence, 91 (76%) LR-TR NONVIABLE, and 6 (5%) EQUIVOCAL, n = 120. Benign post-surgical changes developed in 23 (19%) resection sites, n = 120. 63/115 surgeries (55%) had post-operative recurrence, 40 De Novo, 17 Perilesional, and 6 Intralesional. Conclusion Our conclusions are in two categories: the first assessing the success of CEUS in the assessment of post-surgical treatment sites following liver resections. CEUS can successfully distinguish between unique post-operative appearances such as benign tissue migration, resection VOIDs resembling an intrinsic mass, and true recurrence. CEUS is thus strongly recommended for secondary surveillance following HCC and ICC resection. The second conclusion evaluates the inclusion of resection sites into the CEUS LI-RADS TRA algorithm for ablative therapies. In this regard, we believe that our study was highly successful, improving the perspective of all our staff as to what is important in the assessment of the post-surgical liver on CEUS and the method whereby this information is communicated to our referring clinicians. Graphical Abstract
- 10 May 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (11) , 5520-5530
Ultrasound innovations in abdominal radiology: evaluation of focal liver lesions
Focal liver lesions (FLLs) are common and are often first identified on abdominal ultrasound examinations. Although CT and MRI were historically required to noninvasively characterize many FLLs, introduction of microbubble contrast agents produced a groundbreaking change as contrast enhanced ultrasound (CEUS) showed vascularity to the capillary level for the first time. CEUS shows specific arterial phase enhancement patterns in benign lesions and accurately differentiates malignant lesions based on the timing and intensity of washout. Parametric time of arrival and microvascular imaging techniques can demonstrate vascularity in FLLs with significantly improved sensitivity compared with conventional Doppler techniques. Shear-wave elastography and quantitative ultrasound are generally used to evaluate diffuse liver disease but show promise in evaluation of FLLs. Graphical abstract
- 10 May 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (11) , 5520-5530
Ultrasound innovations in abdominal radiology: evaluation of focal liver lesions
Focal liver lesions (FLLs) are common and are often first identified on abdominal ultrasound examinations. Although CT and MRI were historically required to noninvasively characterize many FLLs, introduction of microbubble contrast agents produced a groundbreaking change as contrast enhanced ultrasound (CEUS) showed vascularity to the capillary level for the first time. CEUS shows specific arterial phase enhancement patterns in benign lesions and accurately differentiates malignant lesions based on the timing and intensity of washout. Parametric time of arrival and microvascular imaging techniques can demonstrate vascularity in FLLs with significantly improved sensitivity compared with conventional Doppler techniques. Shear-wave elastography and quantitative ultrasound are generally used to evaluate diffuse liver disease but show promise in evaluation of FLLs. Graphical abstract
- 24 March 2025
- Published by Springer Nature in Abdominal Radiology
- p. 1-14
Contrast-enhanced ultrasound in pregnancy
There are complex problems related to diagnostic imaging of the pregnant patient Cross sectional imaging with computed tomography (CT) tends to be avoided to due to the risk radiation poses to the fetus and magnetic resonance imaging (MRI) may be limited due to avoidance of gadolinium contrast. While ultrasound (US) is the primary test for imaging in pregnancy, there is limited awareness of contrast-enhanced US (CEUS) as a safe and accurate option for providing similar vascular information to that which is usually provided with contrast-enhanced CT and MRI. Microbubble contrast agents do not cross the placental barrier and have been shown in animal studies to pose no harm to the fetus at doses far above the human dose. The literature on CEUS in pregnancy will be reviewed and the utility and diagnostic accuracy of CEUS for the assessment of acute and chronic maternal conditions and evaluation of neoplastic masses will be demonstrated with case examples. Graphical abstract
- 24 March 2025
- Published by Springer Nature in Abdominal Radiology
- p. 1-14
Contrast-enhanced ultrasound in pregnancy
There are complex problems related to diagnostic imaging of the pregnant patient Cross sectional imaging with computed tomography (CT) tends to be avoided to due to the risk radiation poses to the fetus and magnetic resonance imaging (MRI) may be limited due to avoidance of gadolinium contrast. While ultrasound (US) is the primary test for imaging in pregnancy, there is limited awareness of contrast-enhanced US (CEUS) as a safe and accurate option for providing similar vascular information to that which is usually provided with contrast-enhanced CT and MRI. Microbubble contrast agents do not cross the placental barrier and have been shown in animal studies to pose no harm to the fetus at doses far above the human dose. The literature on CEUS in pregnancy will be reviewed and the utility and diagnostic accuracy of CEUS for the assessment of acute and chronic maternal conditions and evaluation of neoplastic masses will be demonstrated with case examples. Graphical abstract
- 18 January 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (8) , 3476-3487
Occult liver nodules: their detection and characterization with CEUS
Objectives Contrast enhanced ultrasound (CEUS) now joins the ranks of CT and MRI for noninvasive diagnosis of hepatocellular carcinoma (HCC). CEUS LI-RADS provides greater than 95% specificity for diagnosis within LR-5. Unlike CT/MRI, CEUS is nodule based. Currently, LI-RADS does not recommend CEUS of nodules occult or invisible on pre-contrast ultrasound except by experts. This study addresses our ability to find occult nodules using CEUS and to characterize them with CEUS LI-RADS. Methods 100 patients at risk for HCC, 81 with cirrhosis, with occult lesions were retrospectively identified from our archived patient logs. All patients had CEUS examination. Three specialized CEUS techniques (blindshot injection, portal venous (PVP) sweep of the liver, and on-top injection) are used to evaluate nodules. Results There were 114 occult lesions in 100 patients. The origin of 78(68%) lesions was an MRI (n = 69) or CT scan (n = 9) with an observation of abnormal enhancement, generally arterial phase hyperenhancement (APHE). All these patients had blindshot CEUS injection looking for a correlate with APHE. The remainder of occult lesions (n = 36)(32%) were first detected during CEUS, generally as washout foci on PVP sweeps or incidental APHE or washout nearby other targets. All washout areas had subsequent on-top injection to assess for APHE. Application of CEUS LI-RADS algorithm categorized 26 LR-5, 34 LR-4, and 5 LR-M. CEUS upgraded LI-RADS category of 24/50(48%) occult lesions reported on CT/MRI. 29(25%) occult lesions were offered treatment and from categories LR-5 and LR-M, 5 had biopsy confirmation and 15 were treated. From both sources, MR/CT and CEUS, there were 12 occult lesions scanned for treatment response, categorized as 7 LR-TR viable, 1 LR-TR nonviable, and 4 LR-TR equivocal on CEUS. Conclusion Our study shows we can find and characterize occult nodules using CEUS techniques and CEUS LI-RADS algorithm, with positive impact on clinical management. Graphical abstract
- 18 January 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (8) , 3476-3487
Occult liver nodules: their detection and characterization with CEUS
Objectives Contrast enhanced ultrasound (CEUS) now joins the ranks of CT and MRI for noninvasive diagnosis of hepatocellular carcinoma (HCC). CEUS LI-RADS provides greater than 95% specificity for diagnosis within LR-5. Unlike CT/MRI, CEUS is nodule based. Currently, LI-RADS does not recommend CEUS of nodules occult or invisible on pre-contrast ultrasound except by experts. This study addresses our ability to find occult nodules using CEUS and to characterize them with CEUS LI-RADS. Methods 100 patients at risk for HCC, 81 with cirrhosis, with occult lesions were retrospectively identified from our archived patient logs. All patients had CEUS examination. Three specialized CEUS techniques (blindshot injection, portal venous (PVP) sweep of the liver, and on-top injection) are used to evaluate nodules. Results There were 114 occult lesions in 100 patients. The origin of 78(68%) lesions was an MRI (n = 69) or CT scan (n = 9) with an observation of abnormal enhancement, generally arterial phase hyperenhancement (APHE). All these patients had blindshot CEUS injection looking for a correlate with APHE. The remainder of occult lesions (n = 36)(32%) were first detected during CEUS, generally as washout foci on PVP sweeps or incidental APHE or washout nearby other targets. All washout areas had subsequent on-top injection to assess for APHE. Application of CEUS LI-RADS algorithm categorized 26 LR-5, 34 LR-4, and 5 LR-M. CEUS upgraded LI-RADS category of 24/50(48%) occult lesions reported on CT/MRI. 29(25%) occult lesions were offered treatment and from categories LR-5 and LR-M, 5 had biopsy confirmation and 15 were treated. From both sources, MR/CT and CEUS, there were 12 occult lesions scanned for treatment response, categorized as 7 LR-TR viable, 1 LR-TR nonviable, and 4 LR-TR equivocal on CEUS. Conclusion Our study shows we can find and characterize occult nodules using CEUS techniques and CEUS LI-RADS algorithm, with positive impact on clinical management. Graphical abstract
- 1 January 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 314 (1) , e240916
Contrast-enhanced US of High-Risk Indeterminate Focal Liver Observations Categorized as LR-4 or LR-M at CT/MRI
Contrast-enhanced US Liver Imaging Reporting and Data System (LI-RADS) could resolve some indeterminate liver observations (categorized as LR-4 and LR-M at CT or MRI), having a particularly high clinical effect for observations measuring at least 20 mm.
- 1 January 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 314 (1) , e240916
Contrast-enhanced US of High-Risk Indeterminate Focal Liver Observations Categorized as LR-4 or LR-M at CT/MRI
Contrast-enhanced US Liver Imaging Reporting and Data System (LI-RADS) could resolve some indeterminate liver observations (categorized as LR-4 and LR-M at CT or MRI), having a particularly high clinical effect for observations measuring at least 20 mm.
- Open Access
- 25 November 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (6) , 2453-2463
Optimizing US for HCC surveillance
Ultrasound is the primary imaging modality used for surveillance of patients at risk for HCC. In 2017, the American College of Radiology Liver Imaging Reporting and Data Systems (ACR LI-RADS) introduced US LI-RADS to standardize the performance, interpretation, and reporting of US for HCC surveillance, with the algorithm recently updated as LI-RADS US Surveillance v2024. The American Association for the Study of Liver Diseases (AASLD) recommends reporting both the examination-level LI-RADS US Category as well as the US Visualization Score. The US Category conveys the overall findings of the exam and primarily determines follow up recommendations. The US Visualization Score conveys the expected sensitivity of the test and stratifies patients into appropriate surveillance pathways. One of the goals of routine surveillance is the detection of HCC at an early, potentially curable stage. Therefore, optimizing US technique is of critical importance. Increasing North American and worldwide utilization of LI-RADS US Surveillance, which includes technical recommendations, through education and outreach will undoubtedly benefit patients undergoing US HCC surveillance.
- 25 November 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (6) , 2453-2463
Open AccessOptimizing US for HCC surveillance
Ultrasound is the primary imaging modality used for surveillance of patients at risk for HCC. In 2017, the American College of Radiology Liver Imaging Reporting and Data Systems (ACR LI-RADS) introduced US LI-RADS to standardize the performance, interpretation, and reporting of US for HCC surveillance, with the algorithm recently updated as LI-RADS US Surveillance v2024. The American Association for the Study of Liver Diseases (AASLD) recommends reporting both the examination-level LI-RADS US Category as well as the US Visualization Score. The US Category conveys the overall findings of the exam and primarily determines follow up recommendations. The US Visualization Score conveys the expected sensitivity of the test and stratifies patients into appropriate surveillance pathways. One of the goals of routine surveillance is the detection of HCC at an early, potentially curable stage. Therefore, optimizing US technique is of critical importance. Increasing North American and worldwide utilization of LI-RADS US Surveillance, which includes technical recommendations, through education and outreach will undoubtedly benefit patients undergoing US HCC surveillance.
- Open Access
- 11 November 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (5) , 2088-2096
Patient centered HCC surveillance - complementary roles of ultrasound and CT/MRI
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide and is the fastest growing cause of cancer death in the United States (U.S.) In the U.S., current national clinical practice guidelines from the 2023 American Association for the Study of Liver Diseases (AASLD) Practice Guidance and the recently updated Liver Imaging Reporting & Data Systems (LI-RADS) Ultrasound (US) Surveillance v2024 core recommend semi-annual serum α-fetoprotein and US screening of patients deemed to be high risk for developing HCC. In this article, we will explore the transition to a patient-centered approach to HCC surveillance, including the role of the new LI-RADS US Surveillance v2024 core and the use of visualization score for determining ultrasound quality, the known risk factors for poor US image quality, and the potential options for alternative surveillance strategies when US may not be a viable option for certain patients, including multiphasic computed tomography (CT), magnetic resonance imaging (MRI), and several abbreviated MRI protocols.
- 11 November 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (5) , 2088-2096
Open AccessPatient centered HCC surveillance - complementary roles of ultrasound and CT/MRI
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide and is the fastest growing cause of cancer death in the United States (U.S.) In the U.S., current national clinical practice guidelines from the 2023 American Association for the Study of Liver Diseases (AASLD) Practice Guidance and the recently updated Liver Imaging Reporting & Data Systems (LI-RADS) Ultrasound (US) Surveillance v2024 core recommend semi-annual serum α-fetoprotein and US screening of patients deemed to be high risk for developing HCC. In this article, we will explore the transition to a patient-centered approach to HCC surveillance, including the role of the new LI-RADS US Surveillance v2024 core and the use of visualization score for determining ultrasound quality, the known risk factors for poor US image quality, and the potential options for alternative surveillance strategies when US may not be a viable option for certain patients, including multiphasic computed tomography (CT), magnetic resonance imaging (MRI), and several abbreviated MRI protocols.